Podcasts about seqirus

Over in the US so far on Tuesday, Wall Street closed mixed as Fed Chair Jerome Powell signalled concerns over the direction of the US economy amid US tariffs and the possibility of a global trade war. The Dow Jones climbed 0.1% while the S&P500 and Nasdaq dropped 0.2% and 0.6% respectively.In Europe overnight, markets closed higher as investors digested the latest Trump tariff announcements and The European Union plans to retaliate against the US for new steel and aluminium tariffs. The STOXX 600 rose 0.23%, Germany's DAX added 0.56%, the French CAC gained 0.28% and, in the UK, the FTSE100 ended the day up 0.11%.Across the APAC region on Tuesday, markets closed mixed as investors continued digesting the impacts and flow on effects of Trump's latest tariffs. Hong Kong's Hang Seng fell 1.06%, and China's CSI index fell 0.46%, while South Korea's Kospi Index rose 0.71% and Japan's markets were closed for a holiday.The local market started the new trading week lower on Monday before a choppy session that led to a flat close on Tuesday as a sharp sell-off in healthcare stocks weighed on the local index.Trump tariffs continue to dampen investor sentiment and fuel investor and central bank demand for gold stocks, bullion and exposure in portfolios given the safe-haven nature of the precious commodity at a time where economic and market certainty is unclear.CSL's results for the first half out yesterday weighed on the local market and healthcare sector as the healthcare giant fell nearly 5% yesterday despite beating expectations for 2 of the company's 3 divisions. The company's Behring business, which manufactures plasma products and provides collection services in the US, Australia, Europe and more, reported a strong first half with revenue up 10% and gross margin of 51.1% which beat expectations by 20bps. Investors likely sold out of the company amid warnings of FX headwinds to come in H2 and after the Seqirus division posted a 9% decline in revenue on the PCP.Gold miners rocketed again yesterday as the price of the precious commodity jumped over US$2900/ounce for the first time amid increased demand out of central banks and from investors due to the haven nature of the commodity in a time of great uncertainty.What to watch today:Ahead of the midweek trading session here in Australia the SPI futures are anticipating the ASX will open the day up 0.02%.The Aussie dollar has further strengthened against the greenback to buy US$0.62, 95.87 Japanese Yen, 50.70 British Pence and 1 NZ$1.11 cents.On the commodities front this morning, oil is trading 1.21% higher at US$73.19/barrel, gold is down 0.38% at US$2906/ounce and iron ore is up 0.56% at US$106.97/tonne.Trading Ideas:Bell Potter has maintained a buy rating on CSL (ASX:CSL) but have lowered the 12-month price target from $345 to $335 following the release of the company's first half results showing revenue rose 5% but fell 1% short of BPe and NPATA rose 3% but was 4% below BPe. The analyst maintains a buy rating as the Behring division continues its strong growth outlook and positive margin recovery despite the Seqirus division facing headwinds of declining vaccine demand in the US.And Trading Central has identified a bullish signal on QBE Insurance Group (ASX:QBE) following the formation of a pattern over a period of 7-days which is roughly the same amount of time the share price may rise from the close of $20.43 to the range of $21.90 to $22.20 according to standard principles of technical analysis.

Statele membre au aprobat, săptămâna trecută, propunerea Comisiei Europene de a interzice utilizarea substanței chimice bisfenol A (BPA) în fabricarea materialelor care intră în contact cu produsele alimentare. Decizia a fost luată în urma unei consultări publice desfășurată în perioada februarie – martie a.c. și pe baza evaluării științifice a Autorității Europene pentru Siguranța Alimentară (EFSA), care a concluzionat că substanța, care se găsește în plastic, poate produce efecte nocive asupra sistemului imunitar.Interdicția se va aplica, în principal, utilizării bisfenolului în fabricarea ambalajelor, cum ar fi sticlele sau caserolele de plastic reutilizabile, dar și în alte articole de consum, precum dozatoarele de apă sau echipamentele folosite pentru producția de alimente, potrivit unei informări a Reprezentanței Comisiei Europene în România.Măsura urmează să fie examinată de Parlamentul European și de Consiliu și ar putea intra în vigoare, treptat, de la sfârșitul anului.Începând cu 2011, în Uniunea Europeană au fost adoptate mai multe restricții privind utilizarea bisfenolului, de exemplu în producția de biberoane și alte produse pentru copii sau în fabricarea hârtiei termice, iar unele state membre au introdus limitări suplimentare. Continuă simplificarea normelor PACO nouă propunere de simplificare a normelor politicii agricole comune pentru fermierii europeni se află în dezbatere publică până în data de 9 iulie a.c. Comisia Europeană intenționează să elimine obligația statelor membre de a crește la 70% nivelul de monitorizare a suprafețelor și activităților agricole prin fotografii geoetichetate până în anul 2027 și să acorde mai multă flexibilitate în alegerea metodelor de verificare a eligibilității fermelor pentru subvențiile PAC. Astfel, fotografiile digitale cu date despre locație, realizate de fermieri prin intermediul smartphone-urilor, nu ar mai avea prioritate în comparație cu alte tipuri de date cu o valoare cel puțin echivalentă, potrivit propunerii Comisiei.Inițiativa vine după ce rezultatele unui sondaj realizat recent au arătat că un număr semnificativ de fermieri întâmpină probleme în utilizarea dispozitivelor mobile. Platformă pentru mai multă transparență în comerțul cu miereExecutivul european a lansat un apel către experți, pentru crearea unei platforme prin intermediul căreia să stabilească reguli mai clare în privința originii geografice și a compoziției mierii. Grupul de de lucru va ajuta Executivul blocului să îmbunătățească metodele pentru detectarea practicilor frauduloase în lanțul alimentar, informează Direcția Generală pentru Agricultură și Dezvoltare Rurală, DG Agri.Inițiativa a fost lansată săptămâna trecută, o dată cu intrarea în vigoare a normelor revizuite ale UE privind mierea, care stabilesc, între altele, obligativitatea indicării pe etichetă a țărilor de origine în cazul amestecurilor și cotele fiecărui stat, în ordine descrescătoare, de la jumătatea anului 2026.Apelul este deschis până în data de 15 iulie și este adresat tuturor părților interesate din lanțul de aprovizionare cu miere, societății civile și mediului academic, iar prima întâlnire a grupului de experți este de așteptat să aibă loc în luna noiembrie 2024.Blocul comun este al doilea cel mai mare producător de miere din lume după China, dar este și importator net din țări terțe. Apicultura este practicată în toate statele din Uniunea Europeană. Țările UE cu cea mai mare producție de miere sunt România, Spania, Ungaria, Germania, Italia, Grecia, Franța și Polonia.În perioada 2023- 2027, 610 milioane de euro din fonduri naționale și ale Uniunii vor sprijini investițiile în sectorul apicol european, repopularea stupilor și combaterea bolilor albinelor, precum și adaptarea la schimbările climatice. De asemenea, sunt susținute financiar activitățile de promovare și serviciile de consiliere și formare în domeniu. Piața sud-coreeană se deschide pentru carnea de vită europeanăProducătorii francezi și irlandezi de carne de vită vor putea relua exporturile pe piața sud-coreeană, după eliminarea restricțiilor impuse de Republica Coreea în urmă cu mai bine de două decenii din cauza focarelor de encefalopatie spongiformă bovină, cunoscută ca boala vacii nebune.În anul 2001, Coreea de Sud, unul dintre cei mai mari importatori de carne de vită din lume, și-a închis piața pentru furnizorii din 15 state membre ale Uniunii Europene. În 2019, a ridicat barierele comerciale pentru Danemarca și Țările de Jos și acum pentru Franța și Irlanda, informează Comisia Europeană, anticipând că în curând alte țări membre vor putea exporta în statul sud-coreean.Pentru sectorul european al cărnii de vită, comerțul internațional este o sursă importantă de venituri. Anul trecut, exporturile de carne de vită din Uniunea Europeană au depășit un milion de tone, în timp ce importurile au totalizat aproape 290.000 de tone. 15 state membre vor vaccin împotriva gripei aviareSăptămâna trecută, Autoritatea pentru Pregătire și Răspuns în caz de Urgență Sanitară (HERA) din cadrul Comisiei a semnat un contract pentru achiziția a 665.000 de doze de vaccin preventiv Seqirus împotriva gripei aviare, precum și o opțiune de cumpărare a încă 40 de milioane de doze în următorii patru ani, pentru 15 state membre ale Uniunii Europene și din Spaţiul Economic European, informează Executivul blocului într-un comunicat de presă. Primele transporturi pleacă spre Finlanda.Vaccinul este destinat celor mai expuși lucrători la potențiale transferuri de gripă aviară de la păsări sau animale. „Deşi ameninţarea gripei aviare pentru populaţia generală rămâne scăzută, trebuie să protejăm persoanele expuse unui risc mai ridicat, lucrătorii agricoli sau anumiţi medici veterinari”, a declarat Stella Kyriakides, comisar european pentru sănătate și siguranță alimentară, citată în comunicat. Achizițiile sunt voluntare.

In this episode, AANP members Drs. Ruth Carrico and Audrey Stevenson examine real-world influenza vaccination safety and efficacy evidence. They also discuss how nurse practitioners (NPs) can integrate evidence-based strategies to promote influenza vaccination and reduce disparities in vaccination rates. Download a related resource tool for NPs.  To earn 0.75 contact hours of continuing education (CE) credit (0.25 of which may be applied toward pharmacology), you will need the participation code provided at the end of the podcast. To claim your CE credit, log in and register for the activity within the AANP CE Center, then enter the participation code and complete the post-test and evaluation. This podcast was made possible by an independent educational grant from Seqirus.

There have been big changes in flu vaccination in the last few years, with the offer of universal vaccination to those aged 50 or over, as well as to more children in secondary school. In this podcast, Dr Toni Hazell and Dr Uy Hoang discuss the future of flu vaccination. What factors will the JCVI have to consider when deciding who to vaccinate next year, and how much vaccine efficacy and uptake affect the decision making process? Funding was received via sponsorship from Seqirus to cover education on influenza. Seqirus has had no input in the content or been part of any reviews thereof. Editorial and content decisions were made solely by the RCGP.

This week, Stacey is joined by Brian Nunnally, Global Head of Quality Control, Seqirus. Stacey and Brian discuss updates and insights on laboratory operations since the pandemic began. COVID has changed nearly every facet of society, and many of the changes will be permanent, not returning to the “old ways.” While we often take comfort in the status quo, this pandemic has allowed us many positives too, including better digital capabilities, and a better understanding of technological implications on drug development. New knowledge, new ways of working and collaborating, and improved methods of adaptability make this a perfect time to consider evolving our laboratories to meet new demands and maximize patient safety. About Our Guest: Brian K Nunnally, Ph.D., Global Head of Quality Control, Seqirus – A CSL Company Brian is the Head of Quality Control for Seqirus. Being the best quality control unit drives his passion. Prior to this role, he served as the Site Head of Quality for the Holly Springs Seqirus plant. Before joining Seqirus, he worked at Biogen as the Director of Global Stability and also as a Global Regulatory CMC lead. Before joining Biogen, he was in charge of Process Validation for the Pfizer, Sanford, NC site. He is a co-author, with John McConnell, of the book Six Sigma in the Pharmaceutical Industry [2007, Taylor & Francis]. Dr. Nunnally has authored numerous publications in the field of analytical chemistry and operational excellence. He is a member of the CASSS Board of Directors. received two B.S. degrees (1994) from South Carolina Honors College, University of South Carolina, Columbia, and a Ph.D. degree (1998) in chemistry from Duke University, Durham, North Carolina. Prior to taking the Process Validation position, Dr. Nunnally worked in TO&PS Regulatory Affairs. He was responsible for leading the Sanford site's contributions to one of the biggest filings in pharmaceutical history. Prior to joining TO&PS Regulatory, Dr. Nunnally was the Associate Director for GMP Operations in Vaccine Analytical Development at Wyeth. The group he led was responsible for all Reference Standards, Stability, GMP Testing, and Validation for the vaccine candidates Wyeth was developing. Dr. Nunnally has previously worked for Eli Lilly and Company. While at Lilly, he was responsible for leading a Quality Control laboratory devoted to new method development, method optimization, analytical testing for process validation, and analytical testing for manufacturing investigations.   Voices in Validation brings you the best in validation and compliance topics. Voices in Validation is brought to you by IVT Network, your expert source for life science regulatory knowledge. For more information on IVT Network, check out their website at http://ivtnetwork.com.   

On a new episode of World of Promise, host Anthony Farina is joined by Stefan Merlo, Vice President of Commercial Development at Seqirus, and Roberta Duncan, the vaccine company's Vice President, mRNA Program Lead, to discuss what's next in terms of flu vaccine technology. They discuss the potential of aQIVc flu vaccine technology as well as sa-mRNA and how it differs from other mRNA vaccines.

A routine immunization program in long-term care facilities can protect residents who are most at risk of poor outcomes if they contract a vaccine-preventable disease, however systemic challenges contribute to stagnant vaccination rates among residents and low vaccination rates among staff. In this episode, Dr. Barbara Resnick discusses her work in improving immunization rates in long-term care, using behavior motivation techniques to encourage staff and residents to get vaccinated, and what she sees as opportunities for future researchers and practitioners.   Guest: Barbara Resnick, PhD, RN, CRNP, FAAN, FAANP   Sonya Ziporkin Gershowitz Chair in Gerontology, University of Maryland School of Nursing  Host: Justine Sefcik, PhD, RN  Assistant Professor, Drexel University College of Nursing and Health Professions; Co-convener, GSA Interest Group on Nursing  This podcast episode is supported by Seqirus. Content was developed by The Gerontological Society of America (GSA). 

Communicating the risks and benefits of immunization can be challenging, as the language of science may not always be well understood by the public. Dr. Aaron Scherer shares his research on risk communication and infectious disease, what we can learn from outbreak communication with older adults, and his thoughts on future opportunities in the field.   Guest: Aaron Scherer, MA, PhD Assistant Professor of Internal Medicine - General Internal Medicine, University of Iowa  Host: Cheryl Ann Monturo, PhD, MBE, ACNP-BC Senior Nurse Research Scientist Chester County Hospital/Penn Medicine; Professor of Nursing West Chester University  This podcast episode is supported by Seqirus. Content was developed by The Gerontological Society of America (GSA). 

The process of bringing a vaccine to market takes extensive research and safety monitoring. Dr. Gordon Douglas explains the steps from preclinical studies to vaccine licensure, and discusses his own experience developing vaccines at a major manufacturer for 30 years. He also shares lessons learned from clinical trials during the COVID-19 pandemic, including the importance of participant diversity.    Guest: R. Gordon Douglas, Jr, MD  Professor Emeritus, Weill Cornell Medical College   Host: Jo-Ana Chase, PhD, APRN-BC  Associate Professor, Sinclair School of Nursing, University of Missouri Health  This podcast episode is supported by Seqirus. Content was developed by The Gerontological Society of America (GSA). 

Since April 1st 2021 the GP contract agreement regarding the provision of routine vaccination and immunisation in England has changed. In this 30 minute podcast, Dr Dirk Pilat talks to Dr George Kassianos, the National Immunisation Lead of the RCGP. Dr Kassianos explains the new contractual standards and the new vaccination and immunisation domain in the Quality and Outcomes Framework (QOF). Funding was received via sponsorship from Seqirus to cover education on influenza. Seqirus has had no input in the content or been part of any reviews thereof. Editorial and content decisions were made solely by the RCGP.

COVID-19 has offered the biotech industry many lessons. Among the lessons that stands out to Lorna Meldrum is the importance of being prepared for both seasonal flu and the potential for a pandemic outbreak. Meldrum is Vice President of Commercial Operations, International Markets and Pandemic at Seqirus, one of the world's leading influenza vaccine producers, and she's the latest guest on the World of Promise podcast. During her conversation with host Anthony Farina, Meldrum discusses the challenges businesses have faced during the pandemic and how Seqirus is continuing to expand its seasonal and pandemic preparedness efforts in influenza.

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus, a global leader in influenza prevention, discusses data from a first-of-its-kind co-administration study conducted by Novavax of the SARS-CoV-2 vaccine candidate (Novavax, NVX-CoV2373) and an approved influenza vaccine (Seqirus, Flucelvax Quadrivalent and Fluad). He talks about the potential advantages for patients and physicians to co-administer an approved COVID-19 and influenza vaccine, how these findings may impact proposed immunization scheduling for varying age groups and alter CDC recommendations, and the importance of these findings as we approach a critical 2021/22 influenza season while many populations are still in need of a primary COVID-19 vaccine series or booster dose. #COVID #Influenza #Seqirus Dr. Gregg Sylvester serves as the Chief Medical Officer of Seqirus. He has been with the company since 2016, previously serving as Vice President of Medical Affairs. Prior to this, Dr. Sylvester held a variety of senior management positions, including Global Medical Lead for Pfizer's pediatric pneumococcal vaccine and Worldwide Medical Lead for Merck's HPV vaccine and Cabinet Secretary for Delaware's Health & Social Services. Dr. Sylvester is a preventive medicine expert with a passion for disease prevention and health promotion on a local, statewide, and global basis. He has focused his career on developing sound health policy, implementing innovative public health programs and accelerating vaccine use worldwide.

Amidst the development and rollout of COVID-19 vaccines around the globe, conversations around vaccine safety are at an all-time high. On a new episode of the World of Promise podcast, Gregg Sylvester, Chief Medical Officer and Head of Medical Affairs for leading vaccine producer Seqirus, sits down with host Anthony Farina to discuss how Seqirus ensures that its vaccines are safe – the processes that are implemented and why this topic is so important to an organization on the front lines to protect public health.

Dr. Jonathan Edelman, MD, Vice President, Clinical Development at Seqirus discusses the Phase 3 clinical data presented at the 2021 Pediatric Academic Societies (PAS) virtual conference that supports the use of cell-based quadrivalent influenza vaccine (QIVc) in children 6 months to

Innovation was key to creating effective vaccines in the fight against COVID-19. Now, those innovations are being studied for the creation of leading edge influenza vaccines, explains Ethan Settembre, VP, R&D for Seqirus. He talks about how Seqirus is leveraging existing cell and adjuvant technology to deliver effective vaccines and exploring the combination of the two in aQIVc, the company’s next pipeline vaccine. Ethan also speaks to self-amplifying mRNA, the next-generation mRNA platform Seqirus is evaluating for influenza.

Dave Ross, VP of Commercial Operations - North America at Seqirus discusses the recent FDA approval of FLUCELVAX® QUADRIVALENT, Seqirus' cell-based quadrivalent influenza vaccine (QIVc), for an expanded age indication in children two years of age and older. Dave joined Seqirus in October 2017 as Vice President of Commercial Operations – North America. Prior to this, Dave held several senior roles at Sanofi Pasteur, including Head of Marketing and Sales for VaxServe, a subsidiary of Sanofi Pasteur, Head of Strategic Programs for the Global Influenza Franchise, and Head of US Marketing for the Influenza Franchise. He joined Sanofi Pasteur in 2004 from BASF Corporation, where he also held a number of leadership roles in Sales, Marketing, and Finance during his 16-year tenure. Dave has a BS in Finance from Seton Hall University and an MBA from Fairleigh Dickinson University. #Seqirus #QIVc #InfluenzaVaccine

In Episode 12, Season 3 of the Amplifying Scientific Innovation Video Podcast, Dr. Sophia Ononye-Onyia, Founder and CEO of The Sophia Consulting Firm, interviewed Dr. Loddie Foose, Senior Director, Distributor and Emerging Markets, Seqirus and Founder and Global Lead, WIH Give Back, Healthcare Businesswomen's Association (HBA). Here, Dr. Foose shares personal anecdotes of her mission and results-driven leadership journey, industry outlook and her personal and professional commitment to volunteerism and philanthropy. For full transcript, please visit: https://sophiaconsultingfirm.com/blogs-and-articles/f/amplifying-scientific-innovation-dr-loddie-foose-seqirus-hba

In 2020, COVID-19 dominated the headlines and much of the focus for people who work in biotechnology. While the global pandemic continues, there is hope in the vaccines currently being distributed throughout the world. At the same time, seasonal influenza remains a concern. On a new episode of the World of Promise podcast, Dave Ross, Vice President, Commercial Operations North America, for Seqirus, discusses how his organization’s expertise in influenza vaccines could help with the distribution and immunization practices necessary to combat COVID-19. He also shares additional insights from his team’s work with influenza and how it relates to the COVID-19 pandemic.

Every week we breakdown a company in a refreshingly simple way. In this episode, Dan and Albert talk about CSL Limited. CSL is the one of largest global biotech companies in the world. It is listed on the Australian Securities Exchange and operates to deliver science therapies such as plasma-derived immunoglobulins for the treatment of immune deficiencies and neurological conditions, in its CSL Behring division, and influenza vaccines, in its Seqirus division. In this episode we cover: CSL's two business divisions, CSL Behring and Seqirus How blood and plasma donations occur What plasma-derived therapies CSL Behring have in the pipeline What COVID-19 means for CSL's vaccine operations Whether CSL can continue to innovate and stay ahead of the competition Follow and subscribe to our content. CSL Plasma Coupon. All information contained in this podcast is for education and entertainment purposes only. It is not intended as a substitute for professional financial, legal or tax advice. The hosts of Fresh Capital are not financial professionals and are not aware of your personal financial circumstances. Any opinions expressed herein are not recommendations or advice. Please consult a licensed financial professional before you invest. For more information visit our website at https://freshcapital.show/

The flu campaign this year is likely to be bigger than ever, with increased numbers eligible and a likely higher uptake than usual among the previous eligibility groups. In this podcast Dr Toni Hazell talks to Dr Jonathan Leach about the choice of vaccine for different patients, both this year and next, as well as how to fit in the flu and COVID-19 vaccinations safely and how long needs to be left between the two.  The podcast was funded by an educational grant from Seqirus to cover education on influenza and the role of vaccines as a prevention. Seqirus has not had any input in the content or been part of any reviews thereof. Editorial and content decisions were made solely by the RCGP. 

On this episode of "World of Promise," host Anthony Farina interviews Steve Marlow, General Manager of Seqirus, one of the world's leading flu vaccine businesses. Steve also has 20 years of experience in biotech and he talks about the increased demand for flu vaccines during this year's Northern Hemisphere flu campaign. 

Dr. Gregg Sylvester, chief medical officer of Seqirus, discusses the importance of vaccinating against the seasonal flu amid the COVID pandemic, and how the two viruses should be considered in light of each other.

The Australian share market is eyeing a lift of 0.9% at the open. With one day left until the U.S. election, amid the uncertainty investors exercised caution, with the Dow Jones, S&P500 and Nasdaq losing 0.6%, 1.2% and 2.5% respectively.Oil holds at a five-month low at US$35.79 on demand concerns with U.S. COVID-19 cases hitting an all time high, while Germany and France entered new lockdowns last week.What to watch today:AMP (ASX:AMP) confirmed its take-over offer from Ares Management Corporation is for $1.85 per share. On Friday AMP closed at $1.53, so expect a rally today.Westpac (ASX:WBC) reported it full year results, reporting a cash earnings of $2.61b which was less than UBS's forecast of $2.62b.Results are out today for CSR (ASX:CSR). Local trading ideas:Bell Potter reiterated Medical Developments (ASX:MVP) as a Buy, but trimmed its price target to $7.50, implying 38% upside in the year. MVP has a new strategy for the green whistle in Europe and hired CSL's former head of Seqirus as its CEO.Citi reiterated Incitec Pivot (ASX:IPL) as a Buy with a $2.40 price target, expecting fertilisers to drive earnings growth in FY21.Bell Potter reiterated Immutep (ASX:IMM) as a Speculative Buy with a 60 cent target, implying 131% upside in the year.Rio Tinto (ASX:RIO), Mortgage Choice (ASX:MOC) and PKS Holdings (ASX:PKS) are all showing bullish charting signals according to Trading Central.

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus discusses real-world evidence on the company’s cell-based quadrivalent influenza vaccine (QIVc), which was published in the peer-reviewed medical journal "Vaccine". The study shows the value of cell-based quadrivalent influenza vaccine in preventing influenza-related hospitalization in the U.S. 2017/18 season.

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus discusses real-world evidence on the company's MF59® Adjuvanted, Trivalent Influenza Vaccine that was recently published in the peer-reviewed medical journal "Vaccine". The study demonstrated that this vaccine was more effective than a standard-dose non-adjuvanted trivalent seasonal vaccine in preventing influenza-related medical office visits and hospitalizations/ER visits in adults 65+ during the 2017/18 U.S. influenza season.

In this podcast Dr Tom Kneale, a GP and Faculty Educator from North Wales and Dr Jessica Watson, a GP from Bristol and a NIHR Research Fellow at the University of Bristol talk to Dr Barbara Noble about how we can distinguish between flu and COVID-19. Drawing on his clinical experience, Tom talks about the common symptoms of COVID-19, which can help differentiate it from flu as well as some of the more unusual presentations of COVID he has seen in his practice. Jess talks about the importance of testing and also its limitations and Tom highlights the at-risk groups to develop complications of COVID and the red flags we should look for in patients with COVID-19 and flu. The podcast was funded through an educational grant from Seqirus to cover education on influenza and the role of vaccines as a prevention. Seqirus has had no input in the content or been part of any reviews thereof. Editorial and content decisions were made solely by the RCGP.

Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus discusses the background on the new formulation of FLUAD® QUADRIVALENT, the first and only adjuvanted quadrivalent influenza vaccine, and its importance. It was developed to help protect adults 65 years and older against seasonal influenza.

Dr. Russell Basser, MD, Chief Scientist and Senior VP of Research and Development at Seqirus, discusses the FDA approval of Seqirus's AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted). This is the first-ever adjuvanted, cell-based pandemic influenza vaccine to protect against influenza A (H5N1) – a subtype of influenza that the U.S. Centers for Disease Control and Prevention says has strong pandemic potential.

Vaccine Hesitancy: Scope and Solutions  Evaluation and Credit: https://www.surveymonkey.com/r/MedChat10   Target Audience             This activity is targeted towards internal medicine, family medicine, pediatrics, and urgent care.   Statement of Need In January 2019, the World Health Organization included ‘vaccine hesitancy’ as one of the top 10 threats to global health.  Providers should be aware of current philosophies towards vaccine hesitancy, be current on the AAP vaccination schedule, and be knowledgeable in techniques to talk with families that are vaccine hesitant. Objectives At the conclusion of this offering, the participant will be able to: Define vaccine hesitancy. Describe factors that influence a family's tendency to be vaccine hesitant. Discuss effective strategies to address vaccine hesitancy with parents. Understand the scientific data about the safety and efficacy of vaccines and risks of non-vaccination. Moderator Mark J. McDonald, MD, CPE, FAAP Medical Director, Norton Children’s Hospital & Norton Children’s Medical Center Professor, Department of Pediatrics Division of Pediatric Critical Care University of Louisville School of Medicine Speaker Gary S. Marshall, MD Professor of Pediatrics Chief, Division of Pediatric Infectious Diseases University of Louisville School of Medicine Speaker Disclosure The speaker has the following conflicts of interest to disclose:  Advisory Board, Consultant, Grant Recipient, Honoraria and Research – GSK, Merck, Pfizer, Sanofi, and Seqirus.   Moderator and Planner Disclosures  The moderator and planners for this activity have no potential or actual conflicts of interest to disclose. Commercial Support  This activity has not received commercial support.   Physician Credits   American Medical Association   Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.   Designation Norton Healthcare designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.     Date of Original Release | December 2019 Course Termination Date | December 2020 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org   Resources for Additional Study   Vaccine Hesitancy, History, and Human Nature: The 2018 Stanley A. Plotkin Lecture https://academic.oup.com/jpids/article-abstract/8/1/1/5099088?redirectedFrom=fulltext   The Vaccine Handbook: A Practical Guide for Clinicians, 8E "The Purple Book"  https://pcibooks.com/books/view/49   Vaccine Hesitancy: Where We Are and Where We Are Going https://www.ncbi.nlm.nih.gov/pubmed/28774498   Vaccine Hesitancy in Pediatric Primary Care Practices https://www.ncbi.nlm.nih.gov/pubmed/29947574   Vaccine Hesitancy: Causes, Consequences, and a Call to Action https://www.ncbi.nlm.nih.gov/pubmed/26337116  

Dr. Gregg Sylvester, Vice President of Medical Affairs at Seqirus discusses their portfolio of influenza vaccines with the majority of doses coming from its adjuvanted and cell-based technology platforms. There is a range of options for children aged six months and older and the first-and-only adjuvanted seasonal influenza vaccine developed for people aged 65 and older.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Chiesi, Roche, Società Marco Antonetto, AstraZeneca, Viela Bio, MedImmune, Icon, Shionogi, Seqirus, JSB Solutions, Syneos Health, Adecco.Persone: Massimo Scaccabarozzi (Farmindustria), Nuala Murphy (Icon).Nuove terapie: Xofluza, belimumab, emicizumab.Patologie: influenza, Lupus Eritematoso Sistemico, emofilia A.Lavoro: Quality Assurance Consultant, Clinical Monitoring Project Lead, CRA.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano LagravineseIn questa puntata parliamo di:Aziende: EMA, Chiesi, Roche, Società Marco Antonetto, AstraZeneca, Viela Bio, MedImmune, Icon, Shionogi, Seqirus, JSB Solutions, Syneos Health, Adecco.Persone: Massimo Scaccabarozzi (Farmindustria), Nuala Murphy (Icon).Nuove terapie: Xofluza, belimumab, emicizumab.Patologie: influenza, Lupus Eritematoso Sistemico, emofilia A.Lavoro: Quality Assurance Consultant, Clinical Monitoring Project Lead, CRA.Ogni mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/Hai un dispositivo Apple? Seguici e abbonati al podcast tramite la app iPod http://nelfarmaceutico.link/pharma-apple

Today in FirstWord: